1. Introduction
===============

Ionotropic glutamate receptors are the major excitatory amino acid neurotransmitter receptors in the vertebrate central nervous system (CNS). There are three functionally distinct receptor subclasses: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), kainate and N-methyl-D-aspartate (NMDA) \[[@B1-molecules-19-01034]\]. AMPA receptors mediate most of the fast excitatory amino acid transmission in the CNS \[[@B2-molecules-19-01034],[@B3-molecules-19-01034]\]. Attention has focused on drugs that modulate AMPA receptors because of their potential to enhance memory and treat certain pathologies \[[@B4-molecules-19-01034]\]. Positive allosteric modulators of AMPA may have an advantage over direct-acting agonists or compounds that promote glutamate release, in that such drugs could increase glutamatergic tone, without the obvious liability for direct receptor-mediated excitotoxicity \[[@B5-molecules-19-01034]\].

Ampakines are small benzamide compounds that are positive allosteric modulators of AMPA receptors in the mammalian brain. Ampakines were initially derived from the nootropic drug aniracetam which was discovered by Ito *et al.* \[[@B6-molecules-19-01034]\]. Several ampakine compounds (see [Figure 1](#molecules-19-01034-f001){ref-type="fig"}), including 1-BCP, CX516, CX554, CX546 and CX614 can facilitate synaptic plasticity and improve learning and memory in both animals and humans \[[@B7-molecules-19-01034]\].

![Chemical structures of ampakines.](molecules-19-01034-g001){#molecules-19-01034-f001}

These compounds contain as common element a benzamide core, usually in the form of a benzoylpiperidine or a benzoylpyrrolidine. They play a potential therapeutic role in the treatment of neurodegenerative disorders, cognitive impairment, depression, Alzheimer's disease and schizophrenia \[[@B8-molecules-19-01034]\]. They have also been shown to be effective in animal models to treat various neuronal disorders \[[@B9-molecules-19-01034]\] and to enhance viability of neurons \[[@B10-molecules-19-01034]\], probably by promoting expression of growth factors \[[@B11-molecules-19-01034]\].

In this paper, we synthesized several benzamide derivatives which contain a benzamide core and studied their unexpected anti-fatigue activity in the laboratory. To this end we first investigated their anti-fatigue activity by weight-loaded forced swimming tests using a mouse model.

Numerous methods have been developed toward the synthesis of benzamide derivatives. Formation of the amide bond has been one of the most widely studied reactions in organic chemistry \[[@B12-molecules-19-01034]\]. It has been taken for granted that amide bond formation is easily realized by reacting an activated carboxylic acid with an amine.

Generally, most amides are prepared by the condensation of carboxylic acids and amines in the presence of dehydrating reagents, such as B(OMe)~3~, TsCl/Py, TiCl~4~, Ph~2~POCl, Ph~3~P/PySSPy, *N,N\'*-dicyclohexylcarbodiimide (DCC), cyanuric chloride, 2-halo-*N*-methylpyridinium, and (benzotriazol-1-yl) oxy-tris(dimethylamino)phosphonium hexafluorophosphate (BOP), or the carbonylation of aryl halides with amines in the presence of Pd(OAc)~2~, and CO, *etc.* \[[@B13-molecules-19-01034]\]. These methods all have some advantages and disadvantages.

As a result, we report in this paper a convenient approach for the synthesis of amides. Substituted benzoic acids were first treated with N-hydroxysuccinimidyl trifluoroacetate (NHS-TFA). Then, the resulting intermediates were treated with piperidine, morpholine or pyrrolidine to give the target compounds. Unexpectedly, crystals of the intermediate or target compounds were also obtained. All compounds were analyzed via FT-IR, ^1^H-NMR and elemental analysis. The anti-fatigue activity of the benzamide derivatives in weight-loaded forced swimming mice was then investigated. Detailed results and discussion are elaborated in the following sections.

2. Results and Discussion
=========================

2.1. Synthesis and Structural Confirmation
------------------------------------------

Benzamide derivatives are typically prepared by chlorination of benzoic acids followed by amidation of the resulting acid chlorides with an amine compound. Although the purified product can be obtained by flash column chrmatography, difficulties can't be avoided if using this method \[[@B14-molecules-19-01034]\]. 1-BCP was also prepared by the reaction of piperonaldehyde with an equimolar amount of piperidine at 100 °C in the presence of RuH~2~(PPh~3~)~4~ catalyst \[[@B15-molecules-19-01034]\]. A specific catalyst was used in this method. Beller and co-workers used CataCxium A at 80--130 °C and 2 bar CO pressure as the ligand for primary amide synthesis from various substituted aryl bromides and heteroaryl bromides \[[@B16-molecules-19-01034]\]. Recently, palladium-based homogeneous catalysts were also reported for substrates such as benzyl chlorides and aryl chlorides \[[@B17-molecules-19-01034]\].

In this paper, piperonylic acid was treated with *N*-hydroxysuccinimidyl trifluoroacetate (NHS-TFA) at room temperature ([Scheme 1](#molecules-19-01034-f005){ref-type="scheme"}). Then, the intermediate was reacted with piperidine to give the target compound 1-BCP, which could be easily purified by recrystallization from ethanol. The approach provided an efficient and environmentally friendly pathway to synthetic benzamide compounds \[[@B18-molecules-19-01034]\] in good to excellent yields. A total of ten benzamide derivatives were synthesized. The compounds were characterized by elemental analysis, FT-IR, ^1^H-NMR and X-ray crystallography. The information provided should be useful in the area of medical or pharmaceutical applications.

![Synthesis of benzamide derivatives.](molecules-19-01034-g005){#molecules-19-01034-f005}

2.2. Crystal Structures
-----------------------

Single crystals of compounds **a**, **a2** and **e2** were obtained by recrystallization and their structures were further confirmed by X-ray diffraction determination. The data of compounds **a**, **a2** and **e2** are deposited as CCDC Nos. 815292, 960811 and 960813, respectively. The perspectives and packing views are shown in [Figure 2](#molecules-19-01034-f002){ref-type="fig"} and [Figure 3](#molecules-19-01034-f003){ref-type="fig"}, respectively. The crystal data, details concerning data collection and structure refinement are listed in [Table 1](#molecules-19-01034-t001){ref-type="table"}.

![ORTEP drawings of molecules **a**, **a2** and **e2** with 30% probability displacement ellipsoids.](molecules-19-01034-g002){#molecules-19-01034-f002}

![View of the molecular packing in **a**, **a2** and **e2**.](molecules-19-01034-g003){#molecules-19-01034-f003}

molecules-19-01034-t001_Table 1

###### 

Crystal data and structure refinement for **a**, **a2** and **e2**.

                                           a                                   a2                     e2
  ---------------------------------------- ----------------------------------- ---------------------- ----------------------
  CCDC Deposit No.                         815292                              960811                 960813
  Empirical formula                        C~12~H~9~NO~6~                      C~12~H~13~NO~4~        C~14~H~19~NO~5~
  Formula weight                           263.20                              235.23                 281.30
  Temperature (K)                          296(2)                              296(2)                 296
  Wavelength (Å)                           0.71073                             0.71073                0.71073
  Crystal system                           Monoclinic                          Orthorhombic           Triclinic
  Space group                              P2(1)/n                             P bca                  P-1
  a (Å)                                    8.7694(11)                          14.595(3)              8.6577(9)
  b (Å)                                    6.2631(8)                           7.7849(14)             9.5460(10)
  c (Å)                                    22.168(3)                           20.112(4)              9.8578(10)
  α (°)                                    90                                  90                     64.1760(10)
  β (°)                                    94.814(2)                           90                     77.037(2)
  γ (°)                                    90                                  90                     71.6540(10)
  Volume (Å^3^)                            1213.3(3)                           2285.1(7)              692.44(12)
  Z                                        4                                   8                      2
  D~calc~ (g/cm^3^)                        1.441                               1.368                  1.349
  Abs.coefficient (mm^−1^)                 0.118                               0.104                  0.096
  F(000)                                   544                                 992                    300
  Crystal size (mm^3^)                     0.14 × 0.11 × 0.10                  0.20 × 0.10 × 0.10     0.39 × 0.27 × 0.20
  θ limit (°)                              1.84 to 25.10                       2.46 to 25.00          2.31 to 25.00
  Ranges/indices *h. k. l.*                −10/10, −7/6, −26/26                −15/17, −9/9, −23/17   −9/10, −9/11, −11/11
  Refinement method                        Full-matrix least-squares on F^2^                          
  Reflections collected/ unique/R~int~     5777 / 2165/ 0.043                  10446/2001/0.033       3490/ 2432/0.0205
  Completeness to θ = 25.10°               99.6%                               99.6%                  99.3%
  Data/restraints/parameters               2165/0/173                          2001/0/155             2432/0/185
  Goodness of fit on F^2^                  1.088                               1.023                  1.085
  R~1~, wR~2~                              0.0456, 0.1199                      0.0589, 0.1553         0.0404, 0.1261
  Extinction coefficient                   0.020(4)                            0.0028(11)             0.120(12)
  Largest diff. peak and hole(e. Å ^−3^)   0.149 and −0.161                    0.489 and −0.219       0.155 and −0.186

The crystals of 3-benzodioxole-5-carboxylic acid 2,5-dioxo-1-pyrrolidinyl ester (**a**) are monoclinic, space group P2(1)/n with four molecules per unit cell. The O (6) atom lies within the mean plane of the benzene, as indicated by O(6)-C(10)-C(11)-C(12) torsion angle of −179.16°. The O(5) atom is also in the mean plane of the benzene, as indicated by the O(6)-C(10)-C(11)-O(5) torsion angle of 0.6(2)°. All carbon and oxygen atoms of piperonyl are in a plane. The succinimide ring also forms a plane. The dihedral angle between the mean plane of the piperonyl and succinimide rings is 74.69°. In the crystal packing, as shown in [Figure 3](#molecules-19-01034-f003){ref-type="fig"}, weak intermolecular hydrogen bonds are observed (showed as dashed lines).

The crystals of compound **a2** are orthorhombic, space group Pbca with eight molecules per unit cell. The torsion angles of C(12)-N(1)-C(9)-C(10) and C(11)-O(4)-C(10)-C(9) \[53.7(3)° and 58.5(3)°, respectively\] show that the morpholine ring is in a typical chair conformation. The dihedral angle between the mean plane of benzene and a plane formed by N(1), C(9) and C(12) is 89.8°. In the crystal packing, as shown in [Figure 3](#molecules-19-01034-f003){ref-type="fig"}, adjacent molecules are crossed stacked through strong offset π···π aromatic stacking interactions. Intermolecular hydrogen bonds are also observed.

The crystals of compound **e2** are triclinic, space group P-1 with two molecules per unit cell. The morpholine ring is also is a typical chair conformation. In the crystal packing, as shown [Figure 3](#molecules-19-01034-f003){ref-type="fig"} intermolecular hydrogen bonds are also observed (showed as dashed lines).

2.3. Effect on Forced Swimming Capacity
---------------------------------------

The forced swimming capacities are shown in [Figure 4](#molecules-19-01034-f004){ref-type="fig"}. There are significant differences in the swimming time to exhaustion between the control group and each treatment group. The swimming times to exhaustion of the caffeine (positive control group), **b3**, **d3**, and **e3** groups were 1052 ± 148 s, 1310 ± 85 s, 1348 ± 139 s, and 1378 ± 105 s, respectively. Thus, the swimming times to exhaustion of the **b3**, **d3**, and **e3** groups were significantly longer than those of the caffeine group (*p* \< 0.05). It is worthwhile to note that **b3**, **d3**, and **e3** have a common pyrrolidine ring. But what is the real reason? Further observation and study are needed. On the other hand, the swimming times to exhaustion of the **a2**, **b1**, **b4**, **d1**, **d2**, and **e2** groups were longer than that of the normal saline group. However, there was no significant difference in between the caffeine group and each of the other treatment groups.

![Effects of compounds on the forced swimming time. \*\* *p* \< 0.01 compared with the saline group, \* *p* \< 0.05 compared with the saline group, \# *p* \< 0.05 compared with the caffeine group.](molecules-19-01034-g004){#molecules-19-01034-f004}

3. Experimental
===============

3.1. General Information
------------------------

Melting points were taken on a X-4 micro melting point apparatus and are uncorrected. ^1^H-NMR spectra were recorded out in CDCl~3~ on a Varian Inova-400 spectrometer and chemical shifts were reported relative to internal Me~4~Si. Infrared spectra were obtained as KBr pellets on an Equiox-55 FTIR spectrometer. Elemental analyses were performed with a Vario EL-III instrument. The X-ray diffraction data were collected on a Bruker SMART AREX II CCD diffractometer equipped with a graphite monochromated Mo *Kα* radiation (λ = 0.71073 Å) source by using the ω-2θ scan technique at room temperature. The structure was solved by direct methods with SHELXS-97 \[[@B19-molecules-19-01034]\], and refined using SHELXL-97 \[[@B20-molecules-19-01034]\]. Hydrogen atoms were generated geometrically. Molecular illustrations were prepared using the XP package \[[@B21-molecules-19-01034]\]. CCDC 815292 (for compound **a**), 960811 (for compound **a2**) and 960813 (for compound **e2**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from <http://www.ccdc.cam.ac.uk/conts/retrieving.html> (or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033).

3.2. Synthesis
--------------

### 3.2.1. Preparation of *N*-Hydroxysuccinimidyl Trifluoroacetate (NHS-TFA)

The synthesis of NHS-TFA is shown in [Scheme 2](#molecules-19-01034-f006){ref-type="scheme"}. To trifluoroacetic anhydride (15 ml, 71.2 mmol), *N*-hydroxysuccinimide (5 g, 42.6 mmol) was slowly added with vigorously stirring. On a larger scale, a condenser equipped with a drying tube may be needed. The solution was stirred at room temperature about 4 h until the reaction was completed. The reaction solution was evaporated *in vacuo* to remove trifluoroacetic anhydride and trifluoroacetic acid to give a thick oil. Then, it was further dried below 70 °C until a free-flowing colorless solid was obtained. The product is of good quality if it gives bubbles when dissolved in methanol.

![Preparation of N-hydroxysuccinimidyl trifluoroacetate.](molecules-19-01034-g006){#molecules-19-01034-f006}

### 3.2.2. Synthesis of 3-Benzodioxole-5-carboxylic acid, 2,5-dioxo-1-pyrrolidinyl Ester (**a**)

Piperic acid (1.66 g, 10 mmol) was dissolved in anhydrous THF (50 mL) followed by the addition of anhydrous pyridine (4 mL) and N-hydroxysuccinimidyl trifluoroacetate (NHS-TFA) (6.33 g, 30 mmol). The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in CH~2~Cl~2~ (80 mL) and washed with 1mol/L HCl (3 × 80 mL), followed by saturated brine (3 × 80 mL). The organic layer was dried over anhydrous Na~2~SO~4~, filtered and concentrated to give 3-benzodioxole-5-carboxylic acid, 2,5-dioxo-1-pyrrolidinyl ester (**a**). Single crystals of (**a**) for X-ray diffraction experiments were grown from ethanol-water mixture (1:1). White solid; Yield: 88%; m.p. 152--154 °C; FTIR (cm^−1^): 3103, 2995, 2913, 1771, 1730, 1623, 1485, 1442, 1375, 1263, 1210, 1073, 994, 830; ^1^H-NMR (CDCl~3~) δ: 2.91 (s, 4H), 6.09 (s, 2H), 6.90 (d, 1H), 7.51 (s, 1H), 7.76 (d,1H); Anal. calcd. For C~12~H~9~NO~6~: C, 54.76; H, 3.45; N, 5.32; Found C, 54.72; H, 3.41; N, 5.27.

### 3.2.3. Synthesis of 3,4-Dimethoxybenzoic acid, 2,5-dioxo-1-pyrrolidinyl ester (**b**)

Compound **b** was prepared from 3,4-dimethoxybenzoic acid (1.82 g, 10 mmol) and NHS-TFA (6.33 g, 30 mmol) by the procedure utilized for compound **a**. Compound **b** was obtained as a white solid in 84% yield. FTIR (cm^−1^): 3094, 3023, 2940, 2841, 1734, 1599, 1513, 1458, 1448, 1417, 1373, 1273, 1206, 1143, 1071, 1017, 878, 810; ^1^H-NMR (CDCl~3~) δ: 2.92 (s, 4H), 3.94 (s, 6H), 6.94 (d, 1H, *J* = 8.8 Hz), 7.57 (s, 1H), 7.82 (d, 1H, *J* = 6.8 Hz); Anal. calcd. For C~13~H~13~NO~6~: C, 55.91; H, 4.69; N, 5.02; Found C, 55.89; H, 4.67; N, 5.04.

### 3.2.4. Synthesis of 4-Methoxybenzoic acid, 2,5-dioxo-1-pyrrolidinyl ester (**d**)

This compound was prepared from 4-methoxybenzoic acid (1.52 g, 10 mmol) and NHS-TFA (6.33 g, 30 mmol) by the procedure utilized for compound **a**. Compound (**d**) was obtained as a white solid in 86% yield. m.p. 142--144 °C; FTIR (cm^−1^): 3433, 3111, 2940, 2848, 1766, 1735, 1602, 1514, 1457, 1427, 1377, 1271, 1255, 1216, 1183, 1073, 1022, 984, 847, 757; ^1^H-NMR (CDCl~3~) δ: 2.89 (s, 4H), 3.89 (s, 3H), 6.97 (d, 2H, *J* = 8.8 Hz), 8.09 (d, 2H, *J* = 8.8 Hz).

### 3.2.5. Synthesis of 3,4,5-Trimethoxybenzoic acid, 2,5-dioxo-1-pyrrolidinyl Ester (**e**)

This compound was prepared from 3,4,5-trimethoxybenzoic acid (2.12 g, 10 mmol) and NHS-TFA (6.33 g, 30 mmol) by the procedure utilized for compound **a**. Compound (**e**) was obtained as white solid in 80% yield. m.p. 125--127 °C; FTIR (cm^−1^): 2997, 2952, 1763, 1734, 1588, 1504, 1469, 1422, 1339, 1260, 1241, 1203, 1166, 1128, 1078, 989, 892, 750; ^1^H-NMR (CDCl~3~) δ: 2.91(s, 4H), 3.92(s, 9H), 7.38(s, 2H).

### 3.2.6. Synthesis of Compounds **a1** and **a2**

3-Benzodioxole-5-carboxylic acid, 2,5-dioxo-1-pyrrolidinyl ester (2.63 g, 10 mmol) was dissolved in CH~2~Cl~2~ (50 mL) followed by the addition of piperidine (2 mL). The resultant mixture was stirred at room temperature for 2 h. The mixture was washed with 1 mol/L HCl (3 × 80 mL) and saturated brine (3 × 80 mL), and then dried over anhydrous Na~2~SO~4~. The solvent was removed under reduced pressure and the residue was crystallized from ethanol as needles. The compound **a1** was obtained as a white powder. Compound **a2** were prepared according to the same procedure. Single crystals of compound (**a2**) for X-ray diffraction experiments were grown from ethanol.

*N-(3,4-methylenedioxybenzoyl) piperidine* (**a1**). Needle-like solid; Yield: 83%; m.p. 51--52 °C (lit. \[[@B22-molecules-19-01034]\]: 51--52 °C); FTIR (cm^−1^): 3071, 3006, 2926, 2853, 1713, 1607, 1445, 1282, 1248, 1077, 1034, 929, 802; ^1^H-NMR (CDCl~3~) δ: 1.56--1.67 (m, 6H), 3.43 (t, 4H), 6.00 (s, 2H), 6.80 (d, 1H), 6.89 (s, 1H), 6.92 (d, 1H). Anal. calcd. For C~13~H~15~NO~3~: C, 66.97; H, 6.52; N, 5.97; Found C, 66.94; H, 6.48; N, 6.00.

*N-(3,4-methylenedioxybenzoyl) morpholine* (**a2**). Needle-like solid; Yield: 80%; m.p. 82--84 °C (lit. \[[@B23-molecules-19-01034]\]: 83--84 °C); FTIR (cm^−1^): 3433, 3040, 2974, 2899, 2859, 1620, 1494, 1444, 1368, 1342, 1283, 1246, 1108, 1037,940, 833; ^1^H-NMR (CDCl~3~) δ: 3.69 (s, 8H), 6.00 (s, 2H), 6.83 (d, 1H, *J* = 8.0 Hz), 6.91 (s, 1H), 6.93 (d, 1H, *J* = 8Hz); Anal. calcd. For C~12~H~13~NO~4~: C, 61.27; H, 5.57; N, 5.95; Found C, 61.59; H, 5.52; N, 5.98.

### 3.2.7. Synthesis of Compounds **b1**, **b3** and **b4**

These compounds were prepared from 3,4-dimethoxybenzoic acid, 2,5-dioxo-1-pyrrolidinyl ester and piperidine (pyrrolidine or 4-methylpyridine) by the procedure utilized for compound **a1**.

*N-(3,4-Dimethoxybenzoyl) piperidine* (**b1**). White solid; Yield: 84%; m.p. 35--36 °C (lit. \[[@B24-molecules-19-01034]\]: 35--37 °C); FTIR (cm^−1^): 3443, 2943, 2855, 1617, 1580, 1518, 1432, 1331, 1267, 1137, 1018, 870; ^1^H-NMR (CDCl~3~) δ: 1.55--1.68 (m, 6H), 3.45--3.65 (m, 4H), 3.86 (s, 6H), 6.86 (d, 1H, *J* = 8.0 Hz), 6.97 (d, 1H, *J* = 8.0 Hz), 6.98 (s, 1H).

*N-(3,4-Dimethoxybenzoyl) pyrrolidine* (**b3**). Colorless oil; Yield: 83%; FTIR (cm^−1^): 3437, 2972, 2935, 2875, 1612, 1575, 1512, 1454, 1417, 1384, 1328, 1249, 1176, 1120, 1022, 869, 821, 758; ^1^H-NMR (CDCl~3~) δ: 1.87 (t, 2H, *J* = 6.4 Hz), 1.96 (t, 2H, *J* = 6.4 Hz), 3.50 (t, 2H, *J* = 6.0 Hz), 3.64 (t, 2H, *J* = 6.4 Hz), 3.91 (s, 6H), 6.85 (d, 1H, *J* = 8.0 Hz), 7.12 (d, 1H, *J* = 8.8 Hz), 7.14 (s,1H).

*(3,4-Dimethoxyphenyl)(4-methyl-1-piperidinyl) methanone* (**b4**). Colorless oil; Yield: 82%; FTIR (cm^−1^): 3444, 2957, 2863, 1631, 1517, 1437, 1324, 1271, 1141, 1072, 818; ^1^H-NMR (CDCl~3~) δ: 0.98 (d, 3H, *J* = 5.6 Hz), 1.15--1.24 (m, 2H), 1.61--1.79 (m, 4H), 3.90 (s, 6H,), 6.85 (d, 1H, *J* = 8.0 Hz), 6.97 (d, 1H, *J* = 8.4 Hz), 6.98 (s, 1H).

### 3.2.8. Synthesis of Compound **d1**--**d3**

These compounds were prepared from 4-methoxybenzoic acid, 2,5-dioxo-1-pyrrolidinyl ester and piperidine (morpholine or pyrrolidine) by the procedure utilized for compound **a1**.

*N-(4-Methoxybenzoyl) piperidine* (**d1**). Colorless oil; Yield: 80%; ^1^H-NMR (CDCl~3~) δ: 1.58--1.67 (m, 6H), 3.30--3.71 (m, 4H), 3.83 (s, 3H), 6.90 (d, 2H, *J* = 8.4 Hz), 7.37 (d, 2H, *J* = 8.4 Hz). The properties match those reported in the literature \[[@B25-molecules-19-01034]\].

*N-(4-Methoxybenzoyl) morpholine* (**d2**). Colorless oil. Yield: 82%; FTIR (cm^−1^): 3427, 3188, 2931, 2859, 1764, 1690, 1645, 1610, 1494, 1459, 1321, 1254, 1229, 1168, 1109, 1051, 1028, 838, 757, 706; ^1^H-NMR (CDCl~3~) δ: 3.69 (s, 4H), 3.84 (s, 3H), 6.92 (d, 2H, *J* = 8.4 Hz), 7.39 (d, 2H, *J* = 8.4 Hz). The properties match those reported in the literature \[[@B13-molecules-19-01034]\].

*N-(4-Methoxybenzoyl) pyrrolidine* (**d3**). White solid; Yield: 85%; m.p. 76--77 °C (lit. \[[@B26-molecules-19-01034]\]: 78.4--78.8 °C); FTIR (cm^−1^): 3521, 3111, 3082, 2847, 1766, 1735, 1602, 1514, 1457, 1427, 1377, 1271, 1255, 1217, 1183, 1074, 1022, 984, 847, 757; ^1^H-NMR (CDCl~3~) δ: 1.85-1.90 (m, 2H), 1.92--1.97 (m, 2H), 3.48 (t, 2H, *J* =6.4 Hz), 3.65 (t, 2H, *J* = 6.8 Hz), 3.84 (s, 3H), 6.90 (d, 2H, *J* = 8.8 Hz), 7.52 (d, 2H, *J* = 8.8 Hz).

### 3.2.9. Synthesis of Compounds **e2** and **e3**

Compounds **e2** and **e3** were prepared from 3,4,5-trimethoxybenzoic acid, 2,5-dioxo-1-pyrrolidinyl ester and morpholine or pyrrolidine by the procedure utilized for compound **a1**. Single crystals of compound **e2** for X-ray diffraction experiments were grown from ethanol.

*N-(3,4,5-Trihydroxybenzoyl) morpholine* (**e2**). White solid; Yield: 79%; m.p. 97--99 °C (lit. \[[@B12-molecules-19-01034]\]: 96--98 °C); FTIR (cm^−1^): 3430, 2974, 2934, 2871, 1765, 1637, 1586, 1449, 1416, 1327, 1233, 1132, 958, 854; ^1^H-NMR (CDCl~3~) δ: 3.69--3.71 (m, 4H), 3.87 (s, 9H), 6.63 (s, 2H).

*N-(3,4,5-Trihydroxybenzoyl) pyrrolidine* (**e3**). White solid; Yield: 84%; m.p. 182--183 °C. (lit. \[[@B27-molecules-19-01034]\]: 183--186 °C); ^1^H-NMR (CDCl~3~) δ: 1.89 (dd, 2H, *J* = 7.4 Hz, 6.0 Hz), 1.97 (dd, 2H, *J* = 6.8 Hz, 6.4 Hz), 3.46 (t, 2H, *J* = 6.8 Hz), 3.64 (t, 2H, *J* = 6.8 Hz), 3.86 (s, 9H), 6.75 (s, 2H).

3.3. Anti-Fatigue Activity Assessment of Benzamide Derivatives
--------------------------------------------------------------

### 3.3.1. Animals

Six-week-old male Kunming mice (18--22 g, specific pathogen-free grade, SPF) were obtained from the Academy of Experimental Animal Center of The Fourth Military Medical University (Xi'an, China). Mice were maintained under normal conditions: 21--26 °C temperature, 60%--70% relative humidity, 12:12 h dark/light cycle, and free access to laboratory standard diet and water. All mice were quarantined and adapted for 7 days after arriving. All animal experiments were conducted under institutional guidelines and approved by the Ethical Committee for Animal Care and Use of the Fourth Military Medical University.

### 3.3.2. Anti-Fatigue Activity

The anti-fatigue activity of benzamide derivatives was evaluated by the weight loaded swimming model in mice. The model is a reliable measure of anti-fatigue treatment as established in both laboratory animals and humans \[[@B28-molecules-19-01034],[@B29-molecules-19-01034],[@B30-molecules-19-01034]\]. All mice were randomly divided into 12 groups, two control groups and ten treatment groups, seven mice per group. Benzamide derivatives were dissolved in carboxymethylcellulose sodium (CMC) 5 g/L aqueous solution, respectively. One control group received the same volume of saline solution. Another control group received caffeine as a positive control group. Benzamide derivatives were given to mice at concentrations of 0.1 mmol/kg body weight. Samples were orally administered into mice using a feeding atraumatic needle, once per day at 1:00--3:00 pm for one week. After each treatment, all groups of the mice were allowed to rest 30 min and were forced to swim for ten minutes to become accustomed to swimming. The size of swimming pool was designed as 50 cm × 50 cm × 40 cm, filled with fresh water at 30 ± 2 °C. A tin wire (5% of body weight) was loaded on the tail root of the mouse. The mice were assessed to be exhausted when they failed to rise to the surface of water to breathe within a 7 s period \[[@B31-molecules-19-01034]\]. At the end of the session, the mice were removed from the water, dried with a paper towel, and placed back in their home cages. Water in the container was drained after each session. The swimming time to exhaustion was used as the index of the forced swimming capacity.

### 3.3.3. Statistical Analysis

Data were analyzed using SPSS 13.0 version. The results were expressed as the mean ± S.E.M. The data were subjected to one-way analysis of variance (ANOVA) followed by Tukey--Kramer *post-hoc* analysis. The level of *p* \< 0.05 was used as the criterion of statistical significance.

4. Conclusions
==============

In the current study, we have established for the first time a rapid and highly efficient method for the synthesis of benzamide derivatives. The structures of the compounds have been determined by FTIR and ^1^H-NMR spectroscopy, elemental analysis and X-ray diffraction of select examples (compounds **a**, **a2** and **e2)**. The crystal structures have potential applications in identifying the binding site for allosteric modulators of the AMPA receptor, and should be useful in the area of medical or pharmaceutical applications.

Preliminary studies suggest that compound **b3**, **d3** and **e3** increased swimming time to exhaustion in weight-loaded forced swimming mice. They have potential application in developing new drug candidates with anti-fatigue activity. Because a large number of complex mechanisms may be involved in the exercise-induced fatigue, further research including molecular study is required to evaluate the anti-fatigue mechanism.
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